Immunotherapy with Bet v 1 derived contiguous overlapping peptides: results of a phase I/IIa clinical trial in birch pollen allergic volunteers

被引：0
|
作者：
Spertini, F. [1 ]
Perrin, Y. [1 ]
Longaretti, Pellaton C. [1 ]
Barbier, N. [1 ]
Thierry, A. [1 ]
Audran, R. [1 ]
Charlon, V [2 ]
Reymond, C. [2 ]
机构：
[1] CHU Vaudois, Div Immunol & Allergy, Lausanne, Switzerland
[2] Anergis SA, Epalinges, Switzerland
来源：
ALLERGY | 2010年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
8
引用
收藏
页码：4 / 4
页数：1
相关论文
共 38 条
  • [31] Feasibility of iNKT cell and PD-1+CD8+T cell-based immunotherapy in patients with lung adenocarcinoma: Preliminary results of a phase I/II clinical trial
    Cheng, Xiaobo
    Wang, Jing
    Qiu, Chenli
    Jin, Yanling
    Xia, Bili
    Qin, Ran
    Hu, Huiliang
    Yan, Jia
    Zhang, Xiaoyan
    Xu, Jianqing
    CLINICAL IMMUNOLOGY, 2022, 238
  • [32] Phase I/IIa Clinical Trial of Human Embryonic Stem Cell (hESC)-Derived Retinal Pigmented Epithelium (RPE, OpRegen) Transplantation in Advanced Dry Form Age-Related Macular Degeneration (AMD): Interim Results
    Banin, Eyal
    Barak, Adiel
    Boyer, David S.
    Do, Diana V.
    Ehrlich, Rita
    Jaouni, Tareq
    McDonald, Richard
    Tealander, David G.
    Gurevich, Maria
    Cohen, Ohad
    Razag, Ghesal
    Hogge, Gary S.
    Reubinoff, Benjamin
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)
  • [33] Phase I/IIa clinical trial of human embryonic stem cell (hESC)-derived retinal pigmented epithelium (RPE, OpRegen®) transplantation in advanced dry form age-related macular degeneration (AMD): interim results
    Banin, Eyal
    Hemo, Yitzchak
    Jaouni, Tareq
    Marks-Ohana, Devora
    Stika, Shelly
    Zheleznykov, Svetlana
    Obolensky, Alexey
    Gurevich, Maria
    Irving, Charles S.
    Reubinoff, Benjamin
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [34] Phase I/IIa Clinical Trial of Human Embryonic Stem Cell (hESC)-Derived Retinal Pigmented Epithelium (RPE, OpRegen) Transplantation in Advanced Dry Form Age-Related Macular Degeneration (AMD): Interim Results
    Riemann, Christopher D.
    Banin, Eyal
    Barak, Adiel
    Boyer, David S.
    Ehrlich, Rita
    Jaouni, Tareq
    McDonald, Richard
    Telander, David
    Keane, Michael
    Ackert, Jessica
    Ferguson, Mark D.
    Ben-Shabat, Avi
    Mones, Jordi
    Angelini, Diana
    Hogge, Gary S.
    Reubinoff, Benjamin
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [35] Phase I/IIa Clinical Trial of Human Embryonic Stem Cell (hESC)-Derived Retinal Pigmented Epithelium (RPE, Opregen®) Transplantation in Advanced Dry Form Age-Related Macular Degeneration (AMD): Interim Results
    Banin, Eyal
    Hemo, Yitzchak
    Jaouni, Tareq
    Marks-Ohana, Devora
    Gurevich, Maria
    Cuzzani, Oscar
    Boyer, David S.
    Reubinoff, Benjamin
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [36] Safety and immunogenicity of a virus-like, particle pandemic influenza A (H1N1) 2009 vaccine: Results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers
    Low, Jenny G. H.
    Lee, Lawrence S.
    Ooi, Eng Eong
    Ethirajulu, Kantharaj
    Yeo, Pauline
    Matter, Alex
    Connolly, John E.
    Skibinski, David A. G.
    Saudan, Philippe
    Bachmann, Martin
    Hanson, Brendon J.
    Lu, Qingshu
    Maurer-Stroh, Sebastian
    Lim, Sam
    Novotny-Diermayr, Veronica
    VACCINE, 2014, 32 (39) : 5041 - 5048
  • [37] MVX-ONCO-1: First in man, Phase I clinical trial combining encapsulation cell technology and irradiated autologous tumor cells for personalized cell-based immunotherapy. Safety, feasibility and clinical outcome results
    Migliorini, D.
    Vernet, R.
    Belkouch, M. C.
    Luy, P.
    Blaser, S.
    Ancrenaz, V.
    Blazek, N.
    Grandjean, N.
    Wasem, J.
    Janin, B.
    Harboe-Schmidt, P.
    Grogg, J.
    Bouche, N.
    Mach, N.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S114 - S114
  • [38] Three-Year Safety Results of SAR422459 (EIAV-ABCA4) Gene Therapy in Patients With ABCA4-Associated Stargardt Disease: An Open-Label Dose-Escalation Phase I/IIa Clinical Trial, Cohorts 1-5
    Parker, Maria a.
    Erker, Laura r.
    Audo, I. S. A. B. E. L. L. E.
    Choi, D. O. N. G. S. E. O. K.
    Mohand-said, S. A. D. D. E. K.
    Sestakauskas, K. A. S. T. Y. T. I. S.
    Benoit, P. A. T. R. I. C. K.
    Appelqvist, T. E. R. E. N. C. E.
    Krahmer, M. E. L. I. S. S. A.
    Segaut-prevost, C. A. R. O. L. I. N. E.
    Lujan, Brandon j.
    Faridi, A. M. B. A. R.
    Chegarnov, Elvira n.
    Steinkamp, Peter n.
    Ku, C. R. I. S. T. Y.
    Palma, Mariana matioli da
    Barale, Pierre-olivier
    Ayelo-scheer, S. A. R. A. H.
    Lauer, A. N. D. R. E. A. S.
    Stout, T. I. M.
    Wilson, David j.
    Weleber, Richard g.
    Pennesi, Mark e.
    Sahel, JOSe A. L. A. I. N.
    Yang, P. A. U. L.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2022, 240 : 285 - 301
1234